Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $18.00 target price on the stock.

Several other equities research analysts also recently weighed in on ARTV. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $7.13 on Wednesday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $7.75. The business has a 50 day simple moving average of $4.68 and a 200 day simple moving average of $3.92. The stock has a market capitalization of $175.04 million, a P/E ratio of -2.08 and a beta of 2.16.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03. Equities analysts expect that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in ARTV. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter worth about $41,000. Bank of America Corp DE grew its holdings in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth $53,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics in the second quarter worth $58,000. Finally, Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.